Open AccessTherapeutic strategy using phenotypic modulation of cancer cells by differentiation‐inducing agents
Author(s) -
Honma Yoshio,
Akimoto Miho
Publication year - 2007
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2007.00575.x
Subject(s) - phenotype , cancer cell , modulation (music) , cancer research , cancer , biology , microbiology and biotechnology , computational biology , genetics , gene , physics , acoustics
A low concentration of differentiation inducers greatly enhances the in vitro and in vivo antiproliferative effects of interferon (IFN)α in several human cancer cells. Among the differentiation inducers tested, the sensitivity of cancer cells to IFNα was most strongly affected by cotylenin A. Cotylenin A, which is a novel fusicoccane diterpene glycoside with a complex sugar moiety, affected the differentiation of leukemia cells that were freshly isolated from acute myelogenous leukemia patients in primary culture. Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and its receptor DR5 were early genes induced by the combination of cotylenin A and IFNα in carcinoma cells. Neutralizing antibody to TRAIL inhibited apoptosis, suggesting that cotylenin A and IFNα cooperatively induced apoptosis through the TRAIL signaling system. Combined treatment preferentially induced apoptosis in human lung cancer cells while sparing normal lung epithelial cells. In an analysis of various cancer cell lines, ovarian cancer cells were highly sensitive to combined treatment with cotylenin A and IFNα in terms of the inhibition of cell growth. This treatment was also effective toward ovarian cancer cells that were refractory to cisplatin, and significantly inhibited the growth of ovarian cancer cells as xenografts without apparent adverse effects. Ovarian cancer cells from patients were also sensitive to the combined treatment in primary cultures. Combined treatment with cotylenin A and IFNα may have therapeutic value in treating human cancers including ovarian cancer. ( Cancer Sci 2007; 98: 1643–1651)